A number of firms have modified their ratings and price targets on shares of U.S. Bancorp (NYSE: USB) recently: 4/7/2026 – U.S. Bancorp had its price target lowered by JPMorgan Chase & Co. from $62.00 to $58.00. They now have an “underweight” rating on the stock. 3/31/2026 – U.S. Bancorp had its price target lowered […]

A number of firms have modified their ratings and price targets on shares of Duke Energy (NYSE: DUK) recently: 4/15/2026 – Duke Energy had its price target raised by JPMorgan Chase & Co. from $138.00 to $139.00. They now have a “neutral” rating on the stock. 4/10/2026 – Duke Energy was downgraded by Capitol Sec […]

EOG Resources (NYSE: EOG) recently received a number of ratings updates from brokerages and research firms: 4/15/2026 – EOG Resources had its price target raised by Roth Mkm from $110.00 to $134.00. They now have a “neutral” rating on the stock. 4/14/2026 – EOG Resources had its price target lowered by Citigroup Inc. from $150.00 […]

Otis Worldwide (NYSE: OTIS) has recently received a number of price target changes and ratings updates: 4/13/2026 – Otis Worldwide is now covered by Evercore Inc. They set an “outperform” rating and a $100.00 price target on the stock. 4/8/2026 – Otis Worldwide was downgraded by Wolfe Research from “outperform” to “peer perform”. 4/1/2026 – […]

Darling Ingredients (NYSE: DAR) recently received a number of ratings updates from brokerages and research firms: 4/10/2026 – Darling Ingredients had its “sell (d+)” rating reaffirmed by Weiss Ratings. 4/10/2026 – Darling Ingredients had its price target raised by Jefferies Financial Group Inc. from $66.00 to $73.00. They now have a “buy” rating on the […]

Columbia Banking System (NASDAQ: COLB) has recently received a number of price target changes and ratings updates: 4/7/2026 – Columbia Banking System had its price target lowered by Barclays PLC from $30.00 to $29.00. They now have an “equal weight” rating on the stock. 4/7/2026 – Columbia Banking System is now covered by UBS Group […]

Apellis Pharmaceuticals (NASDAQ: APLS) recently received a number of ratings updates from brokerages and research firms: 4/2/2026 – Apellis Pharmaceuticals was downgraded by Roth Mkm from “strong-buy” to “hold”. 4/2/2026 – Apellis Pharmaceuticals had its price target raised by Mizuho from $20.00 to $41.00. They now have a “neutral” rating on the stock. 4/1/2026 – […]